AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS
Latest Information Update: 09 May 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms LIBERTY AD OLE
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 12 Mar 2024 Results assessing the incidence of injection-site reactions (ISR) with long-term dupilumab treatment for up to 5 years, presented at the American Academy of Dermatology annual Meeting 2024
- 12 Mar 2024 Results of Long-Term Safety Data for Dupilumab in a 5-Year, presented at the American Academy of Dermatology annual Meeting 2024
- 12 Mar 2024 Results of Dupilumab Treatment for up to 5 Years Improves Eczema Area and Severity Index Score Across all Anatomical Regions , presented at the American Academy of Dermatology annual Meeting 2024